Cargando…
Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
Identification of biomarkers that predict responses to hypomethylating agents (HMAs) will allow optimal strategies for epigenetic therapy in myelodysplastic syndromes (MDS) to be established. Serum miR-21 was quantitatively measured in 58 MDS patients treated with HMAs and 14 healthy controls. Serum...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913572/ https://www.ncbi.nlm.nih.gov/pubmed/24503739 http://dx.doi.org/10.1371/journal.pone.0086933 |
_version_ | 1782302246760873984 |
---|---|
author | Kim, Yundeok Cheong, June-Won Kim, Yeo-Kyeoung Eom, Ju-In Jeung, Hoi-Kyung Kim, Soo Jeong Hwang, Dohyu Kim, Jin Seok Kim, Hyeuong Joon Min, Yoo Hong |
author_facet | Kim, Yundeok Cheong, June-Won Kim, Yeo-Kyeoung Eom, Ju-In Jeung, Hoi-Kyung Kim, Soo Jeong Hwang, Dohyu Kim, Jin Seok Kim, Hyeuong Joon Min, Yoo Hong |
author_sort | Kim, Yundeok |
collection | PubMed |
description | Identification of biomarkers that predict responses to hypomethylating agents (HMAs) will allow optimal strategies for epigenetic therapy in myelodysplastic syndromes (MDS) to be established. Serum miR-21 was quantitatively measured in 58 MDS patients treated with HMAs and 14 healthy controls. Serum miR-192 was an internal control, and diagnostic performance was evaluated according to receiver operating characteristics (ROCs). ROC analysis indicated that serum miR-21 levels differentiated responders from non-responders with an area under the curve of 0.648 (95% confidence, 0.49 to 0.72). The baseline level of serum miR-21 was significantly lower in the responder group than in the non-responder group (P = 0.041). The overall response rate (ORR) of the high miR-21 group was significantly lower than that of the low miR-21 group (41.2 vs. 73.2%, P = 0.021). Progression-free survival (PFS) was significantly inferior in the high group versus the low group (14.0 vs. 44.5 months, P = 0.001). Multivariate analyses revealed that the initial serum miR-21 level (P = 0.001) and circulating blasts (P = 0.007) were prognostic factors for PFS. Serum miR-21 level was significantly associated with ORR and PFS in MDS patients treated with HMAs. Although validation with a large prospective study is required, serum miR-21 is a potential biomarker of epigenetic therapy in MDS patients. |
format | Online Article Text |
id | pubmed-3913572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39135722014-02-06 Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes Kim, Yundeok Cheong, June-Won Kim, Yeo-Kyeoung Eom, Ju-In Jeung, Hoi-Kyung Kim, Soo Jeong Hwang, Dohyu Kim, Jin Seok Kim, Hyeuong Joon Min, Yoo Hong PLoS One Research Article Identification of biomarkers that predict responses to hypomethylating agents (HMAs) will allow optimal strategies for epigenetic therapy in myelodysplastic syndromes (MDS) to be established. Serum miR-21 was quantitatively measured in 58 MDS patients treated with HMAs and 14 healthy controls. Serum miR-192 was an internal control, and diagnostic performance was evaluated according to receiver operating characteristics (ROCs). ROC analysis indicated that serum miR-21 levels differentiated responders from non-responders with an area under the curve of 0.648 (95% confidence, 0.49 to 0.72). The baseline level of serum miR-21 was significantly lower in the responder group than in the non-responder group (P = 0.041). The overall response rate (ORR) of the high miR-21 group was significantly lower than that of the low miR-21 group (41.2 vs. 73.2%, P = 0.021). Progression-free survival (PFS) was significantly inferior in the high group versus the low group (14.0 vs. 44.5 months, P = 0.001). Multivariate analyses revealed that the initial serum miR-21 level (P = 0.001) and circulating blasts (P = 0.007) were prognostic factors for PFS. Serum miR-21 level was significantly associated with ORR and PFS in MDS patients treated with HMAs. Although validation with a large prospective study is required, serum miR-21 is a potential biomarker of epigenetic therapy in MDS patients. Public Library of Science 2014-02-04 /pmc/articles/PMC3913572/ /pubmed/24503739 http://dx.doi.org/10.1371/journal.pone.0086933 Text en © 2014 Kim et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kim, Yundeok Cheong, June-Won Kim, Yeo-Kyeoung Eom, Ju-In Jeung, Hoi-Kyung Kim, Soo Jeong Hwang, Dohyu Kim, Jin Seok Kim, Hyeuong Joon Min, Yoo Hong Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes |
title | Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes |
title_full | Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes |
title_fullStr | Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes |
title_full_unstemmed | Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes |
title_short | Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes |
title_sort | serum microrna-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913572/ https://www.ncbi.nlm.nih.gov/pubmed/24503739 http://dx.doi.org/10.1371/journal.pone.0086933 |
work_keys_str_mv | AT kimyundeok serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes AT cheongjunewon serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes AT kimyeokyeoung serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes AT eomjuin serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes AT jeunghoikyung serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes AT kimsoojeong serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes AT hwangdohyu serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes AT kimjinseok serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes AT kimhyeuongjoon serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes AT minyoohong serummicrorna21asapotentialbiomarkerforresponsetohypomethylatingagentsinmyelodysplasticsyndromes |